JAVITT'S BIG SPIN = PART 2
Participants: 196 patients
Enrollment at a 2:1 ratio
meant 131 Aviptadil patients were enrolled
and 65 Placebo patients were enrolled
==========================================
Those enrolled were at different stages
OR were treated differently depending on Where enrolled
127 patients treated with High Flow Nasal Cannula (HFNC: n=127)
32 patients treated with Non-Invasive Ventilation (NIV: n=32)
36 patients treated with Mechanical Ventilation (MV: n=36).
================================================
Setting: Ten US-based acute care hospitals,
4 tertiary care teaching hospitals
6 regional hospitals.
====================================================
Results: Overall,
91 of 131 Aviptadil-treated participants survived to day 28
compared to 47 of 65 placebo-treated patients
(70.6% vs 71.7%; P=NS).
NO DIFFERENCE between Placebo and Drug Aviptadil/Zyesami
After 28 days
91 of the Aviptadil patients were alive ( 70.6% )
47 of the 65 Placebo patients were alive ( 71.7%)
( yes a GREATER percent of placebo patients were alive
but there is no difference, because and exactly why small numbers
are meaningless )
============================================
The study was insufficiently powered to detect differences in outcome among patients treated with non-invasive and mechanical ventilation and no differences were detected.
==================================================
So what is LEFT ?
HFNC AT TERTIARY CARE HOSPITALS
NOW NOW the Most RECENT PR
GENEVA, SWITZERLAND / ACCESSWIRE / March 30, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief")
states:
The prespecified analysis of recovery from respiratory failure is clinically and statistically significant in the 127 patients treated by High Flow Nasal Cannula (HFNC) (P = .02), compared to those treated with mechanical or non-invasive ventilation at tertiary care hospitals.
" at tertiary care hospitals. "
NOTICE HE TOOK OUT THE HFNC PATIENTS TREATED AT THE 6 REGIONAL HOSPITALS
Setting: Ten US-based acute care hospitals,
4 tertiary care teaching hospitals
6 regional hospitals.
84% of HFNC patients treated at tertiary medical centers with RLF-100(TM) survived to day 60 compared with 60% of those treated with placebo (P = .007).
""" treated at tertiary medical centers """"
AGAIN HFNC PATIENTS TREATED AT THE 6 REGIONAL HOSPITALS APPEAR TO BE REMOVED
++++ NOTICE --- HE DOES NOT TELL YOU HOW MANY PATIENTS WERE ON HFNC AT THE 4 TERTIARY CARE HOSPITALS
NOR TELL YOU HOW MANY PATIENTS ON HFNC WERE TREATED AT THE 6 REGIONAL HOSPITALS
========================================
========================================
NOW NOW the Most RECENT PR
GENEVA, SWITZERLAND / ACCESSWIRE / March 30, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief")
states:
"""" According to NeuroRx, across all patients and sites, RLF-100(TM) met the primary endpoint for successful recovery from respiratory failure at days 28 (P = .014) and 60 (P = .013) and also demonstrated a meaningful benefit in survival (P = < .001) after controlling for ventilation status and treatment site """""
====================================
In My Opinion that is data mining and quite unfortunate.
xxx.
xx.
x.